NCT02915224View on ClinicalTrials.gov

A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

November 23, 2016

Primary Completion Date

June 8, 2021

Study Completion Date

June 8, 2021

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Chlorambucil

Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.

DRUG

Obinutuzumab

Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.

Trial Locations (11)

11527

General Hospital G. Gennimatas; Hematology Dept., Athens

18537

Metaxa Hospital; Hematology Clinic, Piraeus

26504

University General Hospital of Patra; Internal Medicine Clinic - Hematology Department, Pátrai

54636

AXEPA Pathology Section; A Pathology Clinic, Thessaloniki

411100

University Hospital of Larissa; Hematology Dept., Larissa

068100

University General Hospital of Alexandroupolis; Haemotology, Alexandroup

115 27

Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine, Athens

Laiko General Hospital; Hematology Clinic, Athens

124 62

Attiko Hospital; Haematology Clinic, Athens

711 10

Periph. University General Hospital of Heraklion; Hematology, Heraklion

570 10

General Hospital G. Papanikolaou; Hematology, BMT Unit, Thessaloniki

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02915224 - A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities | Biotech Hunter | Biotech Hunter